Clarithromycin (Klacid 500 mg) and Ubrogepant: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Strong CYP3A4 inhibition can markedly increase ubrogepant exposure.
Clinical significance and safety
Ubrogepant is contraindicated with strong CYP3A4 inhibitors such as the clarithromycin component of Clarithromycin. The combination can markedly increase ubrogepant exposure. A prescriber should select a compatible treatment rather than attempting an unsupervised dose adjustment.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.